This platform consists of a fully autonomous system that utilises an ingestible, ultra-low dose X-ray capsule combined with a state of the art wireless tracking system
Check-Cap has received CE Mark approval for the C-Scan system, an ingestible capsule for preparation-free, colorectal cancer screening. The system offers an alternative to current colon cancer screening methods that require laxative preparation and invasive endoscopic procedures. This platform consists of a fully autonomous system that utilises an ingestible, ultra-low dose X-ray capsule combined with a state of the art wireless tracking system, enabling generation of structural information on the lumen of the colon.
This information is used to create 2D and 3D maps of the colon, allowing physicians to identify pre-cancerous polyps and other abnormalities. C-Scan is designed to improve the patient experience and increase the number of adults screened by eliminating procedural requirements frequently cited as barriers to adherence to screening guidelines such as bowel preparation, fasting, and sedation.
"Achieving CE Mark approval is a significant accomplishment and an important milestone for our company,” said Bill Densel, CEO of Check-Cap. “This is a key validation of C-Scan and its potential as a convenient and comfortable option for identifying polyps in the colon. We look forward to continued progress on our initiatives and remain on target to commence our European post-approval and US pilot trials, each in the 1H2018, as we define marketing and commercialisation pathways throughout 2018."